cutaneous lupus erythematosus
42
MENTIONS
4
EPISODES
2
PODCASTS
Search complete. 42 mentions across 4 episodes found for "cutaneous lupus erythematosus".
Oct 6, 2026
Claudia GüntherHOST
This work is characterizing how litifiblimab affects the underlying biology of cutaneous lupus erythematosus and explores whether different molecular subgroups of patients respond differently to treatment.
Claudia GüntherHOST
So cutaneous lupus erythematosus is a serious autoimmune disease characterized by chronic inflammatory skin lesions driven by multifactorial aberrant immune responses.
Claudia GüntherHOST
The activation of innate and adaptive immune responses including toll-like receptor sensing pathways in plasmacytoid dendritic cells is central to the pathogenesis of CLE.
Claudia GüntherHOST
Litifiblimab is a monoclonal antibody targeting BDCA2, a receptor expressed on PCs, and is designed to inhibit downstream production of type I interferons and other pro-inflammatory mediators.
Claudia GüntherHOST
In the Phase 2 LILAC Part B study of patients with CLE, litifiblimab demonstrated significant improvements in skin disease activity compared with placebo.
Claudia GüntherHOST
However, not all patients responded equally, suggesting the possibility of underlying biological heterogeneity.
Claudia GüntherHOST
The objective of this study was to characterize the effects of litifiblimab on type I interferon and other biological pathways in CLE through transcriptomic analysis and to assess whether baseline molecular endotypes predict treatment response.
Claudia GüntherHOST
Here in this study, whole blood samples were collected from eighty-three participants enrolled in the LILAC Part B and compared with samples from twenty-four matched healthy volunteers.
Maria Dall'EraGUEST
It's so great to be with you today to have this conversation.
Victoria WerthHOST
You're listening to Cutaneous Lupus Conversations, Emerging Therapeutic Insights for Interferon-Driven Disease, a series in which we explore new therapeutic targets and emerging treatments for CLE.
Victoria WerthHOST
In today's episode, we'll be focusing on the role of interferon pathway in CLE and related therapeutic targets that may help us address key disease processes.
Victoria WerthHOST
So, Maria, to start, we would like to set the stage in terms of what's our current understanding of the role of interference signaling as a disease driver in cutaneous lupus.
Maria Dall'EraGUEST
Yes, thank you, Vicki.
Victoria WerthHOST
that can then mediate further interferon production and then also sort of a feedback loop that just continues the process that we see in cutaneous lupus.
Victoria WerthHOST
So, anafromab targets subunit 1 of the type 1 interferon receptor, IFNAR1, and is approved for treating SLE.
Victoria WerthHOST
Is this mechanism of action applicable in CLE as well? We
Victoria WerthGUEST
Great to be here with you, Maria.
Maria Dall'EraHOST
You're listening to Cutaneous Lupus Conversations, Emerging Therapeutic Insights for Interferon-Driven Disease, a series in which we explore new therapeutic targets and emerging treatments for CLE.
Maria Dall'EraHOST
In today's episode, we will discuss how emerging therapies for CLE may be integrated into current treatment strategies.
Maria Dall'EraHOST
Let's kick off this conversation by considering a clinical scenario that we commonly encounter.
Maria Dall'EraHOST
A patient with an inadequate response on conventional therapy who may benefit from an emerging targeted therapy.
Maria Dall'EraHOST
And this is the patient that I will present to you, Vicki.
Maria Dall'EraHOST
This is a patient with active clinically significant CLE.
Maria Dall'EraHOST
who is continuing to have inflammatory lesions despite using adequate photoprotection, which we know is a cornerstone of therapy.
Kenneth KalunianGUEST
It's always a pleasure to interact with you.
Victoria WerthHOST
You're listening to Cutaneous Lupus Conversations, Emerging Therapeutic Insights for Interferon-Driven Disease, a series in which we explore new therapeutic targets and emerging treatments for CLE.
Victoria WerthHOST
In today's episode, we'll be focusing on some emerging therapies in CLE and the latest clinical evidence.
Victoria WerthHOST
Let's begin.
Victoria WerthHOST
So I have a number of questions for you, Dr. Kalunian.
Kenneth KalunianGUEST
Yeah, I think that this is really important for many reasons.
Kenneth KalunianGUEST
As a result, we actually are looking at patients who are in the dermatology realm but also have other manifestations of disease and others who are seen by rheumatologists who don't necessarily have the clarity and expertise of cutaneous manifestations of disease in terms of characterizing whether patients have chronic disease or more acute manifestations of disease.
Kenneth KalunianGUEST
Given that, I mean, I think when you have a patient who primarily has a need for treatment of CLE, it's important to know what drugs primarily hit that and hit that target very well.